New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSS-31 (Elamipretide) vs PT-141 (Bremelanotide)

SS-31 (Elamipretide) vs PT-141 (Bremelanotide)

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
SS-31 (Elamipretide)
Sexual Health & Libido
PT-141 (Bremelanotide)
Summary
SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Half-Life
~2–5 hours
2–3 hours
Admin Route
SubQ
SubQ
Research
Typical Dose
5–10 mg
0.5–1.75 mg
Frequency
Daily to several times per week
As needed (not daily)
Key Benefits
  • Restores mitochondrial function and ATP production
  • Protects inner mitochondrial membrane cardiolipin
  • Reduces mitochondrial reactive oxygen species (ROS)
  • Improves exercise capacity and reduces fatigue
  • Cardioprotective — studied in heart failure trials
  • Renoprotective — reduces ischemic kidney injury
  • Anti-aging via mitochondrial preservation
  • Potential in neurodegenerative disease prevention
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
Side Effects
  • Injection site irritation
  • Nausea (rare)
  • Generally well-tolerated in clinical trials
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
Stacks With